ArticleCureus2026
Bridging the Gap: Infantile Hemangioma Care Variability Among Pediatric Care Physicians in Greece.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infantile hemangiomas (IHs) are the most common benign vascular tumors of infancy, and timely, risk-adapted management is critical to prevent functional and aesthetic complications. Although international evidence-based guidelines are well established, their implementation in everyday primary care practice remains inconsistent. We conducted a pragmatic, cross-sectional, web-based survey between November 2024 and February 2025 to characterize real-world management patterns of IHs among Greek primary care physicians who had completed a nationally accredited e-learning program on IH recognition and treatment. The survey comprised 10 multiple-choice items addressing treatment initiation criteria, pharmacologic strategies, monitoring and imaging practices, and treatment discontinuation. Seventy-four physicians participated, including 48 pediatricians (64.9%) and 26 general practitioners (GPs; 35.1%). Head and neck IHs larger than 2 cm prompted intervention in 40/48 pediatricians (83.3%) and 24/26 GPs (92.3%), compared with significantly lower intervention rates for similarly sized lesions on the trunk or extremities (30/48, 62.5% vs. 10/26, 38.5%; p = 0.048). Ulceration was infrequently recognized as an independent indication for systemic therapy (12/48 pediatricians, 25.0%; 4/26 GPs, 15.4%). Propranolol was widely adopted as first-line treatment; however, initiation most commonly occurred after 12 weeks of age (59/74 physicians, 79.7%), inpatient commencement was strongly favored even in low-risk cases (67/74, 90.5%), and dosing clustered around 2 mg/kg/day (71/74, 95.9%). Treatment discontinuation was typically abrupt (49/74, 66.2%), with structured tapering and post-treatment relapse surveillance infrequently reported. Despite shared theoretical training, substantial variability persists in the real-world management of IHs in Greek primary care, reflecting an implementation gap rather than a lack of knowledge. These findings highlight the need for context-sensitive national guidance emphasizing risk-adapted initiation and dosing, clearly defined imaging thresholds, safe outpatient pathways, and standardized follow-up to improve consistency and equity of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.